Healthcare diagnostics company Labcorp Holdings (NYSE: LH) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 5.6% year on year to $3.52 billion. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $14.7 billion at the midpoint. Its non-GAAP profit of $4.07 per share was 3.2% above analysts’ consensus estimates.

Is now the time to buy LH? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Labcorp’s Q4 results came in below Wall Street’s revenue expectations, leading to a negative market reaction, while management attributed performance to strength in specialty testing and expanded partnerships with hospitals and regional labs. CEO Adam Schechter highlighted the company’s double-digit growth in esoteric testing and the successful integration of recent acquisitions, including Invitae and assets from various health systems. Schechter also acknowledged that lower organic volume growth was partly due to reduced referrals from a major consumer genetic client and mild weather disruptions, but indicated these were largely isolated events. The quarter was further supported by ongoing cost discipline and advancements in automation and artificial intelligence across core laboratory and consumer services.

Looking forward, Labcorp’s guidance for 2026 reflects optimism around continued expansion in specialty testing, the rollout of new central laboratory capabilities, and steady momentum in its hospital partnership pipeline. Management expects both organic volume and pricing to contribute equally to growth, with margin improvements underpinned by the LaunchPad efficiency initiative and targeted capital investments. CFO Julia Wang emphasized plans for “another year of meaningful margin improvement by both segments,” fueled by investments in technology and expansion of high-growth product categories. Schechter cautioned that the outlook incorporates headwinds from healthcare policy changes and seasonal weather, but remains confident in the company’s ability to deliver sustainable growth.

Key Insights from Management’s Remarks

Management attributed Q4 performance to growth in specialty and esoteric testing, expanded hospital partnerships, and successful integration of acquisitions, while noting isolated volume pressures from a large client and weather-related impacts.

• Specialty testing momentum: Labcorp’s double-digit growth in esoteric testing, which includes advanced diagnostics for oncology, neurology, and autoimmune diseases, was a key performance driver. Management emphasized that specialty testing now comprises a larger share of total testing volume and typically leads to additional routine tests for the same patients.
• Hospital and lab partnerships: The company closed or signed 13 new deals with health systems and regional labs, contributing to over $1 billion in added revenue over three years. Schechter described this channel as “a key engine” for future growth and margin stability.
• Product innovation and AI integration: Labcorp launched more than 130 new tests in 2025 and introduced AI-powered solutions to streamline appointment scheduling, test selection, and results reporting. The introduction of Roche’s automated mass spectrometry system and FDA-cleared Alzheimer’s blood test demonstrate ongoing investment in differentiated capabilities.
• Acquisition strategy: Labcorp completed and announced several acquisitions during the quarter, including outreach laboratory assets from Parkview Health and Community Health Systems, and pathology assets from Incyte Diagnostics. These moves are expected to supplement organic growth and expand geographic and service reach.
• Operational efficiency initiatives: The LaunchPad program and targeted cost actions in the Early Development (ED) business improved margins. Management noted that ED restructuring will reduce annual revenue by $50 million but enhance profitability, with most changes completed by Q2 2026.

Drivers of Future Performance

Labcorp expects steady revenue and margin expansion in 2026, driven by specialty testing growth, operational efficiencies, and ongoing hospital partnerships, while monitoring policy and consumer market shifts.

• Specialty and advanced testing expansion: Management anticipates continued high growth in specialty areas such as oncology, neurology, and women’s health, which are expected to grow 2–3 times faster than the broader diagnostics market and drive higher-margin revenue.
• Hospital partnerships and acquisition pipeline: The company sees strong demand from hospitals and regional labs seeking outsourcing solutions due to financial pressures. Management highlighted a robust pipeline of deals, with timing subject to state and federal approvals, and expects these partnerships to be a core source of incremental volume and margin support.
• Margin improvement through efficiency programs: The LaunchPad initiative and streamlining of the Early Development segment are projected to deliver annual savings and margin gains. CFO Julia Wang expects the Biopharma Laboratory Services segment to see greater margin improvement than diagnostics, citing operational changes and ongoing technology investments as key contributors.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will closely watch (1) the pace of specialty test adoption and its impact on Labcorp’s product mix, (2) progress on new and existing hospital partnership deals and their revenue contribution, and (3) the effectiveness of operational efficiency programs, including the LaunchPad initiative and Early Development restructuring. Advances in automation, AI integration, and the ramp-up of central laboratory investments will also be important indicators of execution.

Labcorp currently trades at $269.39, down from $282.63 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.